David Happel is President and Chief Executive Officer of Sagimet Biosciences Inc. (SGMT). The company reported total compensation of $3,239,994 for fiscal year 2025.
| Salary | $630,000 |
|---|---|
| Bonus | $0 |
| Stock awards | $546,360 |
| Option awards | $1,749,751 |
| Non-equity incentive plan | $294,525 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $19,358 |
| Total | $3,239,994 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Sagimet Biosciences Inc. filed April 21, 2026, accession 0001104659-26-046006.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| David Happel this page | President and Chief Executive Officer | $3,239,994 |
| Elizabeth Rozek | Chief Legal and Administrative Officer | $1,496,702 |
| Eduardo Martins | Former Chief Medical Officer | $1,360,841 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Sagimet Biosciences Inc. compensation brief.
David Happel's compensation sits inside Sagimet Biosciences Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.